6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity-Reference-Cited by-同舟云学术

6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity

Published:2002-07-20 Issue:17 Volume:45 Page:3569-3572
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Pellicciari Roberto¹,Fiorucci Stefano¹,Camaioni Emidio¹,Clerici Carlo¹,Costantino Gabriele¹,Maloney Patrick R.¹,Morelli Antonio¹,Parks Derek J.¹,Willson Timothy M.¹

Affiliation:

1. Dipartimento di Chimica e Tecnologia del Farmaco, Università di Perugia, Via del Liceo, 06123 Perugia, Italy, Dipartimento di Medicina Clinica e Sperimentale, Clinica di Gastroenterologia ed Epatologia, Università di Perugia, 06123 Perugia, Italy, and Discovery Research, GlaxoSmithKline, Research Triangle Park, North Carolina 27709

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm025529g

Reference18 articles.

1. Identification of a Nuclear Receptor for Bile Acids

2. Bile Acids: Natural Ligands for an Orphan Nuclear Receptor

3. Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR

Cited by 674 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Selective Agonism of Liver and Gut FXR Prevents Cholestasis and Intestinal Atrophy in Parenterally Fed Neonatal Pigs;2024-09-07

3. Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells;Cancer Letters;2024-08

4. Potential therapeutic strategies for MASH: from preclinical to clinical development;Life Metabolism;2024-07-06

5. Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials;Expert Opinion on Emerging Drugs;2024-07-04